Last edition
News about "MB-204 Phase I clinical trial"
Marvel Biosciences Selects Novotech as CRO for MB-204 Phase-I Trial
Marvel Biosciences selects Novotech as CRO for its phase-I clinical trial of MB-204, a patented adenosine A2A antagonist, following successful cGMP synthesis and GLP toxicology studies.
MB-204 Phase I Clinical Trial | 25/03/2026 | By News Bureau | 175
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members